Abstracts tagged "Anti-drug antibodies"

Abstract Number: 1525 • ACR Convergence 2021
Risk Factors for Anti-infliximab Antibody Formation: Results from a Randomized Controlled Trial
Marthe Brun¹, Guro Goll¹, Kristin Jørgensen², Joseph Sexton¹, Johanna Gehin³, Øystein Sandanger⁴, Inge Olsen⁴, Rolf Anton Klaasen⁴, David Warren⁴, Cato Mørk⁵, Tore Kvien¹, Jørgen Jahnsen², Nils Bolstad⁴, Espen Haavardsholm¹ and Silje Watterdal Syversen¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Akershus University Hospital, Lørenskog, Norway, ³Oslo University Hospital, Lillehammer, Nepal, ⁴Oslo University Hospital, Oslo, Norway, ⁵Akershus Dermatology Center, Lørenskog, Norway
Background/Purpose: Immunogenicity is related to loss of efficacy and safety to TNFα inhibitors and is frequently observed early in the treatment course. The highest rate…
Abstract Number: 586 • 2019 ACR/ARP Annual Meeting
Drug Concentrations and Anti-drug Antibodies Influence in Response to Adalimumab: Results from the BioEfficacySpA Clinical Trial
José Marona¹, Santiago Rodrigues-Manica ², João Lagoas Gomes ¹, Carina Lopes ³, Inês Iria ⁴, Miguel Bernardes ⁵, Helena Santos ⁶, Jose Tavares-Costa ⁷, João Madruga-Dias ⁸, Patrícia Pinto ⁹, Alexandra Bernardo ¹⁰, Sara Maia ¹¹, Jaime Branco ², João Gonçalves ⁴ and Fernando Pimentel-Santos ², ¹Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental; CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Lisbon., Lisbon, Portugal, ²CEDOC, NOVA-Medical School | Hospital Egas Moniz, CHLO, Lisbon, Lisbon, Portugal, ³Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental; CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Lisbon, Lisbon, Portugal, ⁴Faculdade de Farmácia da Universidade de Lisboa; Portugal, Lisbon, Portugal, ⁵Rheumatology, Centro Hospitalar de São João, Porto, Portugal, Porto, Portugal, ⁶Instituto Português de Reumatologia (IPR), Lisbon, Portugal, ⁷ULSAM, Ponte de Lima, Portugal, Ponte de Lima, Portugal, ⁸CHMT, Torres Novas, Portugal, Torres Novas, ⁹Rheumatology Department, CHVNG, Vila Nova de Gaia, Portugal, ¹⁰Rheumatology Department, CHSJ, Porto, Portugal, ¹¹CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Lisbon, Lisbon, Portugal
Background/Purpose: Almost all protein-based biotherapeutics can induce immunogenicity, which may result in loss of efficacy and/or increased risk of adverse reactions. Despite all the efforts…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].